Fatkin D, Seidman CE, Seidman JG. Genetics and disease of ventricular muscle. Cold Spring Harb Perspect Med. 2014;1:a021063.
Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Europace. 2011;13:1077–1109.
Fatkin D, Johnson R, McGaughran J, et al. Position statement on the diagnosis and management of familial dilated cardiomyopathy. Heart Lung Circ. 2017;26:1127–1132.
Sikkema-Raddatz B, Johansson LF, de Boer EN, et al. Targeted next-generation sequencing can replace Sanger sequencing in clinical diagnostics. Hum Mutat. 2013;34:1035–1042.
Pugh TJ, Kelly MA, Gowrisankar S, et al. The landscape of genetic variation in dilated cardiomyopathy as surveyed by clinical DNA sequencing. Genet Med. 2014;16:601–608.
Pua CJ, Bhalshankar J, Miao K, et al. Development of a comprehensive sequencing assay for inherited cardiac condition genes. J Cardiovasc Transl Res. 2016;9:3–11.
Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet. 2011;12:745–755.
Weischenfeldt J, Symmons O, Spitz F, Korbel JO. Phenotypic impact of genomic structural variation: insights from and for human disease. Nat Rev Genet. 2013;14:125–138.
Li X, Montgomery SB. Detection and impact of rare regulatory variants in human disease. Front Genet. 2013;4:67.
Dewey FE, Grove ME, Pan C, et al. Clinical interpretation and implications of whole-genome sequencing. JAMA. 2014;311:1035–1045.
Golbus JR, Puckelwartz MJ, Dellefave-Castillo L, et al. Targeted analysis of whole genome sequence data to diagnose genetic cardiomyopathy. Circ Cardiovasc Genet. 2014;7:751–759.
Roberts AM, Ware JS, Herman DS, et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci Transl Med. 2015;7:270ra6.
Shi L, Zhang Y, Feng L, et al. Multi-omics study revealing the complexity and spatial heterogeneity of tumor-infiltrating lymphocytes in primary liver carcinoma. Oncotarget. 2017;8:34844–34857.
McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–1303.
Gayevskiy V, Roscioli T, Dinger ME, Cowley MJ Seave: a comprehensive web platform for storing and interrogating human genomic variation. BioRxiv https://doi.org/10.1101/258061 (unpublished data in text).
Rehm HL, Bale SJ, Bayrak-Toydemir P, et al. ACMG clinical laboratory standards for next-generation sequencing. Genet Med. 2013;15:733–747.
Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–424.
Uhlén M, Fagerberg L, Hallström BM, et al. Tissue-based map of the human proteome. Science. 2015;347:1260419.
Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013;15:565–574.
Viguera E, Canceill D, Ehrlich SD. In vitro replication slippage by DNA polymerases from thermophilic organisms. J Mol Biol. 2001;312:323–333.
Kircher M, Stenzel U, Kelso J. Improved base calling for the Illumina Genome Analyzer using machine learning strategies. Genome Biol. 2009;10:R83.
Costa MW, Guo G, Wolstein O, et al. Functional characterization of a novel mutation in NKX2-5 associated with congenital heart disease and dilated cardiomyopathy. Circ Cardiovasc Genet. 2013;6:238–247.
Begay RL, Tharp CA, Martin A, et al. FLNC gene splice mutations cause dilated cardiomyopathy. JACC: Basic Transl Sci. 2016;1:344–359.
Dalkilic I, Schienda J, Thompson TG, et al. Loss of filamin C (FLNC) results in severe defects in myogenesis and myotube structure. Mol Cell Biol. 2006;26:6522–6534.
Chevessier F, Schuld J, Orfanos Z, et al. Myofibrillar instability exacerbated by acute exercise in filaminopathy. Hum Mol Genet. 2015;24:7207–7220.
Bolduc V, Marlow G, Boycott KM, et al. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies. Am J Hum Genet. 2010;86:213–221.
Xu J, El Refaey M, Xu L, et al. Genetic disruption of Ano5 in mice does not recapitulate human Ano5-deficient muscular dystrophy. Skelet Muscle. 2015;5:43.
Hoffmann L, Haussmann U, Mueller M, et al. VLCAD enzyme activity determinations in newborns identified by screening: a valuable tool for risk assessment. J Inherit Metab Dis. 2012;35:269–277.
Erdmann J, Daehmlow S, Wischke S, et al. Mutation spectrum in a large cohort of unrelated consecutive patients with hypertrophic cardiomyopathy. Clin Genet. 2003;64:339–349.
Chen SN, Czernusczewicz G, Tan Y, et al. Human molecular genetic and functional studies identify TRIM63, encoding Muscle RING Finger Protein 1, as a novel gene for human hypertrophic cardiomyopathy. Circ Res. 2012;111:907–919.
Uys GM, Ramburan A, Loos B, et al. Myomegalin is a novel A-kinase anchoring protein involved in the phosphorylation of cardiac myosin binding protein C. BMC Cell Biol. 2011;12:18.
Norton N, Li D, Rieder MJ, et al. Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am J Hum Genet. 2011;88:273–282.
Rice AM, McLysaght A. Dosage sensitivity is a major determinant of human copy number variant pathogenicity. Nat Commun. 2017;8:14366.
Barefield DY, Puckelwartz MJ, Kim EY, et al. Experimental modelling supports a role for MyBP-HL as a novel myofilament component in arrhythmia and dilated cardiomyopathy. Circulation. 2017;136:1477–1491.
Froissart R, Guffon N, Vanier MT, et al. Fabry disease: D313Y is an α-galactosidase A sequence variant that causes pesudodeficient activity in plasma. Mol Genet Metab. 2003;80:307–314.
Cirino AL, Lakdawala NK, McDonough B, et al. A comparison of whole genome sequencing to multigene panel testing in hypertrophic cardiomyopathy patients. Circ Cardiovasc Genet. 2017;10:e001768.
Bodi K, Perera AG, Adams PS, et al. Comparison of commercially available target enrichment methods for next-generation sequencing. J Biomol Tech. 2013;24:73–86.
Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol. 2013;10:531–547.
Haas J, Frese KS, Peil B, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2015;36:1123–1135.
Stark Z, Lunke S, Brett GR, et al. Meeting the challenges of implementing rapid genomic testing in acute pediatric care [published online ahead of print March 15, 2018]. Genet Med 2018. https://doi.org/10.1038/gim.2018.37.